FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 171 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New targeted lung cancer screening programme on the horizon September 29, 2022 The Nobel Prize winner helping us treat children’s cancers November 8, 2022 Dad Is Making Baby Giggle, But When He Makes A Sheep... May 21, 2019 Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... November 29, 2021 Load more HOT NEWS Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests New study identifies how obesity may increase the risk of developing... Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma... Research with integrity – referencing work is way more than just...
